GlyTherix Ltd is pleased to announce the execution of a Master Service Agreement with 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO), for the manufacture of GlyTherix’s targeted radiotherapy antibody products for its US clinical trials.
Under the terms of the agreement, 3DI will manufacture and deliver finished clinical unit doses of GlyTherix’s imaging and therapeutic products (89Zr-Miltuximab® and 177Lu-Miltuximab®) from 3DI’s central facility in Little Rock, Arkansas, USA located close to the Global FedEx hub.
3DI will also supply its own cyclotron-produced GMP Zirconium-89 oxalate product for the manufacture of 89Zr-Miltuximab®. The agreement is structured to support GlyTherix’s US manufacturing needs and incorporates potential future product distribution requirements in the Asia-Pacific region.
Read the media release here: GlyTherix_3DI_Media_Release.pdf